Fisher Scientific and Apogent to Merge in $3.7 Billion Transaction

(Portsmouth, NH, USA) in a transaction valued at US$3.7 billion.

Fisher's shareholders will own approximately 57% of the combined company, and Apogent's shareholders will own approximately 43%. The companies anticipate that the transaction, which will establish a $1.1 billion footprint in the high-growth life-science market, will be completed early in the third quarter of the 2004 calendar year.

"Today's announcement represents a major strategic milestone for our company and will create a more integrated and efficient global supply network for our customers,” said Paul M. Montrone, chairman and CEO of Fisher Scientific. "With Apogent Technologies, Fisher Scientific has further enhanced its position in the life-science, scientific-research, and clinical-lab markets and created a stronger platform for growth. Joining forces with Apogent enables Fisher to create efficiencies for our customers and value for our shareholders.”



Related Links:
Fisher Scientific
Apogent Technologies Inc.